scholarly journals A community pharmacist's intervention in antipsychotic drug-induced sexual dysfunction in a patient with schizophrenia

2020 ◽  
Author(s):  
Masaki Maehara ◽  
Masayasu Sugiyama
Keyword(s):  
Early Intervention ◽  
Sexual Dysfunction ◽  
Antipsychotic Drug ◽  
Community Pharmacist ◽  
Side Effect ◽  
Community Pharmacists ◽  
Common Side Effect ◽  
Drug Induced ◽  
First Report

Sexual dysfunction (SD) is a common side effect of antipsychotics. The community pharmacist assessed a patient with SD and suggested a change in prescription from risperidone and haloperidol to aripiprazole that improved SD. This is the first report on amelioration of antipsychotic-induced SD by early intervention by community pharmacists.

scholarly journals Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management

2019 ◽  
Vol 12 ◽  
pp. 175628481988419 ◽  
Author(s):  
Uday N. Shivaji ◽  
Louisa Jeffery ◽  
Xianyong Gui ◽  
Samuel C. L. Smith ◽  
Omer F. Ahmad ◽  
...  
Keyword(s):  
Early Intervention ◽  
Adverse Events ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Management Strategies ◽  
Intestinal Barrier ◽  
Common Side Effect ◽  
Drug Induced ◽  
Immune Balance ◽  
Steroid Refractory

Background: Drug-induced colitis is a known complication of therapies that alter the immune balance, damage the intestinal barrier or disturb intestinal microbiota. Immune checkpoint inhibitors (ICI) directed against cancer cells may result in activated T lymphocyte-induced immune-related adverse events (AEs), including immune-related colitis and hepatitis. The aim of this review article is to summarize the incidence of gastrointestinal (GI) and hepatic AEs related to ICI therapy. We have also looked at the pathogenesis of immune-mediated AEs and propose management strategies based on current available evidence. Methods: A literature search using PubMed and Medline databases was undertaken using relevant search terms pertaining to names of individual drugs, mechanism of action, related AEs and their management. Results: ICI-related GI AEs are common, and colitis appears to be the most common side effect, with some studies reporting incidence as high as 30%. The incidence of both all-grade colitis and hepatitis were highest with combination therapy with anti-CTLA-4/PD-1; severity of colitis was dose-dependent (anti-CTLA-4). Early intervention is associated with better outcomes. Conclusion: ICI-related GI and hepatic AEs are common and clinicians need to be aware. Patients with GI AEs benefit from early diagnosis using endoscopy and computed tomography. Early intervention with oral steroids is effective in the majority of patients, and in steroid-refractory colitis infliximab and vedolizumab have been reported to be useful; mycophenolate has been used for steroid-refractory hepatitis.

Drug-induced akathisia as a cause of distress in spouse caregivers of cancer patients

2011 ◽  
Vol 9 (2) ◽  
pp. 209-212 ◽  
Author(s):  
Mei Wada ◽  
Hiroshi Ito ◽  
Makoto Wada ◽  
Tomomi Wada ◽  
Yukio Tada ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Family Caregivers ◽  
Side Effect ◽  
Terminally Ill ◽  
Common Side Effect ◽  
Major Depressive ◽  
Drug Induced ◽  
Careful Clinical Examination ◽  
Spouse Caregivers ◽  
Spouse Caregiver

AbstractObjective:Family caregivers of cancer patients suffer from physical, psychological, and social distress and therefore are often referred to as second order patients. Akathisia is a common side effect of antipsychotics and antidepressants that causes great discomfort and even agitation and is often described by patients administered these drugs as the most distressing side effect of their treatment. Several studies of akathisia as a cause of distress in cancer patients have been reported. However, akathisia has not been reported as a cause of distress in family caregivers of cancer patients.Method/Case report:A 74-year-old spouse caregiver who was under treatment for major depressive disorder was not able to visit the hospital where her husband, a terminally ill cancer patient, was being treated. Initially, the spouse caregiver thought that she could not visit the hospital because of the symptoms of her depression and her grief about losing her husband. However, careful clinical examination revealed that she was suffering from akathisia in addition to her grief.Results:Discontinuation of her sulpiride treatment resulted in the disappearance of her akathisia symptoms, and therefore she became able to visit the hospital and care for her terminally ill husband.Significance of results:Drug induced akathisia is a cause of distress in spouse caregivers taking certain drugs. It is important for clinicians to realize that family caregivers might suffer from not only socioeconomic, physical, and psychological problems but also side effects of medication.

Sexual side effects in patients treated with desvenlafaxine: An observational study in daily practice

2016 ◽  
Vol 33 (S1) ◽  
pp. s227-s228 ◽  
Author(s):  
B. Navarro ◽  
L. Perez ◽  
L. Erkoreka ◽  
A. Arroita ◽  
I. Perez
Keyword(s):  
Side Effects ◽  
Sexual Dysfunction ◽  
Side Effect ◽  
Daily Practice ◽  
Well Being ◽  
Common Side Effect ◽  
Sexual Side Effects ◽  
Health Centres ◽  
Competing Interest ◽  
Orgasmic Dysfunction

IntroductionSexual function is important for patients’ well-being but it is a common side effect of SSRI and SNRI, included desvenlafaxine.Objectives and aimsEvaluate incidence and characteristics of sexual dysfunction caused by desvenlafaxine in the clinical practice.MethodsOne hundred and thirty-three patients with recently introduced desvenlafaxine treatment are recruited from Barakldo and Uribe-Kosta Mental Health Centres in Biscay, Spain. UKU scale is administered to measure sexual side effects. Statistical analysis is performed using SPSS v.22.ResultsSexual dysfunction is observed in 5 patients (3.7%) at 50 and 100 mg/d (2 and 3 patients, respectively) desvenlafaxine doses. Two patients (1.5%) have experimented more than one sexual side effect. Regarding gender differences, the most frequent sexual dysfunctions are diminished sexual desire (5.5%) and erectile dysfunction (5.5%) in men and orgasmic dysfunction (1.2%) in women (P-values are 0.034; 0.034 and 0.408, respectively). Discontinuation is decided in 60% of patients.ConclusionsDesvenlafaxine has a well-tolerated sexual side effect profile in general population. There are some gender-related differences both in presentation and perception, as it has been described with other drugs, and this should be taken into account by prescriptors.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Drug Induced Encephalopathy in Patients with Chronic Kidney Disease: A Case Series

2018 ◽  
Vol 8 (2) ◽  
pp. 172-176
Author(s):  
Wasim Md Mohosin Ul Haque ◽  
Tabassum Samad ◽  
Muhammad Abdur Rahim ◽  
Shudhanshu Kumar Saha ◽  
Sarwar Iqbal
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Impairment ◽  
Side Effect ◽  
Case Series ◽  
Special Group ◽  
Drug Induced ◽  
Reduced Dose

Drug induced encephalopathy is an established side effect of many drugs when used in a higher dose. Though we do not encounter this side effect frequently in our day to day practice, yet with renal impairment this is not uncommon. Even with a reduced dose many of these can precipitate encephalopathy in this special group of patients. We are presenting here a series of seven such cases of drug induced encephalopathy in patients with renal impairment.Birdem Med J 2018; 8(2): 172-176

A genome-wide association study of nausea incidence in varenicline-treated cigarette smokers

2021 ◽  
Author(s):  
Meghan J Chenoweth ◽  
Caryn Lerman ◽  
Jo Knight ◽  
Rachel F Tyndale
Keyword(s):  
Association Study ◽  
Side Effect ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Common Side Effect ◽  
Drug Transporter ◽  
Transporter Gene ◽  
Cigarette Smokers ◽  
Genome Wide ◽  
A Genome

Abstract Introduction Varenicline is the most efficacious smoking cessation treatment, however long-term cessation rates tend to be <25%. Nausea, the most common side effect of varenicline, observed in ~28% of individuals treated, peaks early following treatment initiation and reduces cessation success. Genetic variation influences treatment response, however genetic contributors to individual differences in side effects are less understood. Methods We conducted a genome-wide association study of nausea incidence at one week following the initiation of varenicline treatment (corresponding to the target quit date) in 189 cigarette smokers of European ancestry (NCT01314001). Additive genetic models examining the likelihood of experiencing any versus no nausea controlled for population substructure, age, and sex. Variants with minor allele frequencies (MAF) ≥ 10% were considered. Results Fifty-seven (30.2%) out of 189 participants reported nausea. The top variant associated with nausea was rs1568209 (OR=2.61 for A vs. G allele; 95% CI=1.65,4.15; P=2.1e-7; MAF=48.7%), mapping to the SLCO3A1 drug transporter gene on chromosome 15. In the same trial, rs1568209 was not associated with nausea in either the nicotine patch (P=0.56; n=181) or placebo (P=0.59; n=174) arms. In varenicline-treated smokers, the incidence of nausea was higher in females (44.6%; n=74) versus males (20.9%; n=115) (P=0.001), however there was no evidence of a difference in the influence of rs1568209 on nausea between the sexes (P for sex*genotype interaction=0.36). Future studies in larger samples are required to test the robustness of this finding. Conclusions Variation in SLCO3A1 may influence the risk for developing nausea in varenicline-treated smokers, which may alter adherence and cessation. Implications Varenicline-associated nausea reduces adherence and limits cessation success. Previous candidate gene association studies showed genetic factors influence nausea on varenicline. This pilot genome-wide investigation of nausea, the most common side effect associated with varenicline treatment and an importance cause of treatment discontinuation, suggests the potential involvement of common variation in the SLCO3A1 drug transporter gene.

scholarly journals Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia

2021 ◽  
Vol 402 ◽  
pp. 113101
Author(s):  
Tyler R. Prestwood ◽  
Roshanak Asgariroozbehani ◽  
Sally Wu ◽  
Sri Mahavir Agarwal ◽  
Ryan W. Logan ◽  
...  
Keyword(s):  
Antipsychotic Drug ◽  
Metabolic Disturbances ◽  
Drug Induced
Sign in / Sign up

Export Citation Format

Share Document